ArticleScientific reports2014
Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- A CRISPR activation screen identifies CH25H as a restriction factor against influenza viruses by targeting accessible cholesterol.Emerging microbes & infections · 2026Article
- Intestinal oxysterol remodeling underlies severe COVID-19 in an aged hamster model.GeroScience · 2026Article
- 25-Hydroxycholesterol restricts human norovirus replication in human intestinal enteroids.Journal of virology · 2025Article
- Targeting ferroptosis for precision medicine in cervical cancer.Apoptosis : an international journal on programmed cell death · 2025Review
- Advances in the Prevention of Cervical Cancer by Anti-Human Papillomavirus Agents.Cancer medicine · 2025Review
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- In silico molecular screening of bioactive natural compounds of rosemary essential oil and extracts for pharmacological potentials against rhinoviruses.Scientific reports · 2024Article
- Oxysterol 25-hydroxycholesterol activation of ferritinophagy inhibits the development of squamous intraepithelial lesion of cervix in HPV-positive patients.Cell death discovery · 2024Article
- 25-Hydroxycholesterol in health and diseases.Journal of lipid research · 2024Review
- Oxysterols in Infectious Diseases.Advances in experimental medicine and biology · 2024Article
- Review
- Advances in the development of antivirals for rotavirus infection.Frontiers in immunology · 2023Review
- Current Trends and Perspectives in Microbial Bioconversions of Steroids.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Cholesterol 25-hydroxylase suppresses avian reovirus replication by its enzymatic product 25-hydroxycholesterol.Frontiers in microbiology · 2023Article
- Dietary Cholesterol Metabolite Regulation of Tissue Immune Cell Development and Function.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2.Nature metabolism · 2022Article
- Oxysterols: From redox bench to industry.Redox biology · 2022Review
- Cholesterol metabolism: from lipidomics to immunology.Journal of lipid research · 2022Review
- Review
- 7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19.The Journal of steroid biochemistry and molecular biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies reported a broad but selective antiviral activity of 25-hydroxycholesterol (25HC) against enveloped viruses, being apparently inactive against non-enveloped viruses. Here we show that 25HC is endowed with a marked antiviral activity against three pathogenic non-enveloped viruses, i.e. human papillomavirus-16 (HPV-16), human rotavirus (HRoV), and human rhinovirus (HRhV), thus significantly expanding its broad antiviral spectrum, so far recognized to be limited to viruses with envelope. Moreover, here we disclose the remarkable antiviral activity of another oxysterol of physiological origin, i.e. 27-hydroxycholesterol (27HC), against HPV-16, HRoV and HRhV. We have also identified a much weaker antiviral activity of other oxysterols of pathophysiological relevance, i.e 7α-hydroxycholesterol, 7β-hydroxycholesterol, and 7-ketocholesterol. These findings suggest that appropriate modulation of endogenous production of oxysterols might be a primary host strategy to counteract a broad panel of viral infections. Moreover, 25HC and 27HC could be considered for new therapeutic strategies against HPV-16, HRoV and HRhV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.